Weight Loss :: FDA not recommend rimonabant for use in obese and overweight patients
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval of rimonabant (ZIMULTI(R)) to the US FDA for use in obese and overweight patients with associated risks factors.